BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10953541)

  • 1. Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
    Dajani EZ; Agrawal NM
    J Assoc Acad Minor Phys; 2000; 11(2-3):28-31. PubMed ID: 10953541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.
    Lanas A; SopeƱa F
    Gastroenterol Clin North Am; 2009 Jun; 38(2):333-52. PubMed ID: 19446262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
    Wolfe MM
    Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study.
    Maiden L; Thjodleifsson B; Seigal A; Bjarnason II; Scott D; Birgisson S; Bjarnason I
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1040-5. PubMed ID: 17625980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
    McCarthy DM
    Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
    Warner TD; Mitchell JA
    FASEB J; 2004 May; 18(7):790-804. PubMed ID: 15117884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.